Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PGD | P52209 | 1/20 | 0.35 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662090 | 1.00 | KMT2A (0.38) | KMT2AMEN1GAATDP1SMN1; SMN2 | |
| SCHEMBL344597 | 0.85 | HDAC3 (0.44) | KMT2AMEN1GAAAAK1LMNA | |
| SCHEMBL344596 | 0.85 | HDAC3 (0.44) | KMT2AMEN1GAAAAK1LMNA | |
| SCHEMBL28086823 | 0.84 | KMT2A (0.39) | KMT2AMEN1GAATDP1SMN1; SMN2 | |
| SCHEMBL28250949 | 0.82 | MEN1 (0.35) | KMT2AMEN1GAAAAK1 | |
| SCHEMBL3325728 | 0.82 | KMT2A (0.39) | KMT2AMEN1GAACYP2D6CA1 | |
| SCHEMBL11048601 | 0.82 | TDP1 (0.33) | TDP1SMN1; SMN2PGDSLC22A6CYP2D6 | |
| SCHEMBL3325735 | 0.82 | KMT2A (0.39) | KMT2AMEN1GAACYP2D6CA1 | |
| SCHEMBL4897617 | 0.81 | KMT2A (0.33) | KMT2AMEN1GAAPGDCYP2D6 | |
| SCHEMBL28184673 | 0.80 | MEN1 (0.34) | KMT2AMEN1GAAAAK1NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2306994-B1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-2306994-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | Amgen, Inc (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7842685-B2 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-11-30 | — | — | US | disclosed |
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | AMGEN INC. (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009154775-A1 | S1P1 RECEPTOR AGONISTS AND USE THEREOF | AMGEN INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| CN-101094691-A | Carrier | IC VEC LTD (GB) | 2007-12-26 | — | — | CN | disclosed |
| EP-1814594-A2 | VECTOR COMPRISING POLYMER MODIFIED SIRNA LIPOSOMES | IC Vec Limited (GB) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006016097-A2 | VECTOR COMPRISING POLYMER MODIFIED SIRNA LIPOSOMES | IC VEC LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| EP-0024965-B1 | FLUORINATED METHYL BETA-ALANINE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MERRELL TORAUDE ET COMPAGNIE (FR) | 1983-04-27 | — | — | EP | disclosed |
| US-4375477-A | ENZYME INHIBITORS | MERRELL TORAUDE ET COMPAGNIE (FR) | 1983-03-01 | — | — | US | disclosed |
| EP-0024965-A1 | Fluorinated methyl beta-alanine derivatives, their preparation and pharmaceutical compositions containing them | MERRELL TORAUDE ET COMPAGNIE (FR) | 1981-03-11 | — | — | EP | disclosed |
| EP-0021883-A2 | N-acyl-amino acid derivatives and pharmaceutical compositions containing them, intermediates and starting compounds | MERRELL TORAUDE ET COMPAGNIE (FR) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029611-A1 | S1P1 receptor agonists and use thereof | S1PR1, S1PR5, S1PR2 | KMT2A 3037/4885MEN1 684/4885GAA 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.